Brokers Set Expectations for YMAB FY2024 Earnings

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) – Brookline Capital Management issued their FY2024 earnings per share (EPS) estimates for Y-mAbs Therapeutics in a research report issued to clients and investors on Wednesday, December 4th. Brookline Capital Management analyst K. Dolliver expects that the company will post earnings per share of ($0.75) for the year. Brookline Capital Management has a “Strong-Buy” rating on the stock. The consensus estimate for Y-mAbs Therapeutics’ current full-year earnings is ($0.66) per share. Brookline Capital Management also issued estimates for Y-mAbs Therapeutics’ Q4 2024 earnings at ($0.23) EPS, Q1 2025 earnings at ($0.22) EPS, Q2 2025 earnings at ($0.22) EPS, Q3 2025 earnings at ($0.21) EPS, Q4 2025 earnings at ($0.29) EPS and FY2025 earnings at ($0.94) EPS.

Y-mAbs Therapeutics (NASDAQ:YMAB) last posted its earnings results on Friday, November 8th. The company reported ($0.16) EPS for the quarter, missing the consensus estimate of ($0.14) by ($0.02). Y-mAbs Therapeutics had a negative return on equity of 24.61% and a negative net margin of 28.22%. The company had revenue of $18.46 million for the quarter, compared to analyst estimates of $23.38 million. During the same period last year, the business earned ($0.18) earnings per share.

YMAB has been the topic of several other reports. Canaccord Genuity Group raised Y-mAbs Therapeutics to a “strong-buy” rating in a report on Tuesday, August 13th. Wedbush restated an “outperform” rating and issued a $23.00 target price on shares of Y-mAbs Therapeutics in a research report on Tuesday, September 10th. Canaccord Genuity Group restated a “buy” rating and issued a $26.00 target price on shares of Y-mAbs Therapeutics in a research report on Tuesday, August 13th. HC Wainwright restated a “buy” rating and issued a $22.00 target price on shares of Y-mAbs Therapeutics in a research report on Friday, November 15th. Finally, Oppenheimer started coverage on Y-mAbs Therapeutics in a research report on Monday, November 18th. They issued an “outperform” rating and a $23.00 target price on the stock. One equities research analyst has rated the stock with a sell rating, seven have given a buy rating and two have given a strong buy rating to the company. According to MarketBeat, the company presently has an average rating of “Buy” and an average target price of $20.89.

Y-mAbs Therapeutics Trading Up 0.2 %

Shares of YMAB opened at $10.28 on Monday. Y-mAbs Therapeutics has a 12 month low of $6.09 and a 12 month high of $20.90. The stock’s 50 day moving average is $13.12 and its two-hundred day moving average is $12.73. The firm has a market cap of $460.44 million, a P/E ratio of -19.04 and a beta of 0.61.

Insider Buying and Selling

In related news, insider Thomas Gad sold 30,000 shares of Y-mAbs Therapeutics stock in a transaction that occurred on Monday, September 16th. The stock was sold at an average price of $12.97, for a total transaction of $389,100.00. Following the transaction, the insider now owns 67,681 shares in the company, valued at approximately $877,822.57. This trade represents a 30.71 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. 22.50% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Y-mAbs Therapeutics

Institutional investors have recently added to or reduced their stakes in the stock. Zurcher Kantonalbank Zurich Cantonalbank purchased a new stake in Y-mAbs Therapeutics in the third quarter valued at $44,000. China Universal Asset Management Co. Ltd. raised its position in Y-mAbs Therapeutics by 66.3% in the third quarter. China Universal Asset Management Co. Ltd. now owns 8,572 shares of the company’s stock valued at $113,000 after purchasing an additional 3,416 shares during the period. Intech Investment Management LLC purchased a new stake in Y-mAbs Therapeutics in the third quarter valued at $133,000. SG Americas Securities LLC purchased a new stake in Y-mAbs Therapeutics in the third quarter valued at $178,000. Finally, Empire Financial Management Company LLC purchased a new stake in Y-mAbs Therapeutics in the third quarter valued at $210,000. Hedge funds and other institutional investors own 70.85% of the company’s stock.

Y-mAbs Therapeutics Company Profile

Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.